S&P 500 E-Mini futures (ESH25) are down -0.92%, andMarch Nasdaq 100 E-Mini futures (NQH25) are down -1.14% this morning as ...

Goldman Sachs trims its staff, cutting what it deems to be the underperformers. This year, VPs stand to be big targets, BI ...

Goldman Sachs named David Dubner as chief operating officer of global mergers and acquisitions, according to a memo seen by ...

Improving economic conditions and a more favorable regulatory environment give Goldman Sachs catalysts to benefit from in the ...

Goldman Sachs initiated coverage of Sionna Therapeutics (SION) with an Early-Stage Biotech designation. Lead assets SION-719 and SION-451 are ...

Usually, only one or two sector weightings vary by more than 3 percentage points from the index levels, or—as is the case currently—none fall outside that range (according to Goldman Sachs ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

ASX 200 futures are up 17pts (+0.21%) as of 8:30 am AEDT. In a nutshell: ASX set to bounce after two-session losing streak ...

Sharon Goldman is an AI reporter at Fortune.Previously, she covered AI for VentureBeat. Sharon has written about digital and enterprise tech for over a decade, for publications and organizations ...

Moderna has said it will open a new R&D and manufacturing facility in the UK which could lead to improved access by NHS patients to mRNA-based vaccines and drug treatments. The facility is the ...

MSD and partner Moderna have started a late-stage trial of their personalised cancer vaccine V940 as a combination with MSD’s PD-1 inhibitor Keytruda for patients with non-small cell lung cancer ...